Clinical trial · Interventional
Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases
An Exploratory Study to Evaluate Biomarkers as Predictive and /or Prognostic Factors of Benefit From Randomized Phase ll Study of mFOLFOX6+Bevacizumab or mFOLFOX6+Cetuximab in Liver Only Metastasis From KRAS Wild Type Colorectal Cancer
NCT01834014CI-TRIAL-00028904ATOM EScompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The correlation between the values of angiogenesis-related growth factors in plasma and efficacy, and biomarkers relevant as prognostic factors or predictive factors for sensitivity or resistance to treatment will be examined exploratively.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
| Liver Metastasis | Colorectal Neoplasm | PROBABILISTIC | 0.70 |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 5-FU | Drug | Fluorouracil | ALIAS |
| Bevacizumab | Drug | Bevacizumab | ALIAS |
| Cetuximab | Drug | Cetuximab | ALIAS |
| l-LV | Drug | — | UNRESOLVED |
| L-OHP | Drug | Oxaliplatin | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- mFOLFOX + Bmab
- description
- mFOLFOX plus bevacizumab
- interventionNames
- Drug: Bevacizumab
- Drug: L-OHP
- Drug: l-LV
- Drug: 5-FU
- type
- ACTIVE_COMPARATOR
- label
- mFOLFOX + Cmab
- description
- mFOLFOX plus cetuximab
- interventionNames
- Drug: Cetuximab
- Drug: L-OHP
- Drug: l-LV
- Drug: 5-FU
Primary outcomes (1)
- measure
- To evaluate the values of angiogenesis-related growth factors in plasma with Progression-free survival (PFS)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Patients who registered the ATOM trial and signed informed consent prior to initiation of any trial-specific procedure and treatment. Exclusion Criteria: * None
References
Publications (0)
Data not yet available
No reference posted for this study.